- Previous Close
9.55 - Open
9.20 - Bid 8.95 x --
- Ask 9.40 x --
- Day's Range
9.20 - 9.20 - 52 Week Range
3.62 - 29.50 - Volume
1 - Avg. Volume
1 - Market Cap (intraday)
96.265M - Beta (5Y Monthly) 1.03
- PE Ratio (TTM)
0.10 - EPS (TTM)
90.11 - Earnings Date Nov 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
www.avalotx.comRecent News: C6K0.F
View MorePerformance Overview: C6K0.F
Trailing total returns as of 11/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: C6K0.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: C6K0.F
View MoreValuation Measures
Market Cap
98.16M
Enterprise Value
20.56M
Trailing P/E
0.11
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
62.33
Price/Book (mrq)
4.97
Enterprise Value/Revenue
26.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-30.64%
Return on Equity (ttm)
-42.52%
Revenue (ttm)
820k
Net Income Avi to Common (ttm)
-8.13M
Diluted EPS (ttm)
90.11
Balance Sheet and Cash Flow
Total Cash (mrq)
81.86M
Total Debt/Equity (mrq)
7.18%
Levered Free Cash Flow (ttm)
39.64M